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ABSTRACT
Significant advances have been made towards understanding the role of immune
cell-tumor interplay in either suppressing or promoting tumor growth, progression, and
recurrence, however, the roles of additional stromal elements, cell types and/or cell
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states remain ill-defined. The overarching goal of this NCI-sponsored workshop was
to highlight and integrate the critical functions of non-immune stromal components
in regulating tumor heterogeneity and its impact on tumor initiation, progression,
and resistance to therapy. The workshop explored the opposing roles of tumor
supportive versus suppressive stroma and how cellular composition and function may
be altered during disease progression. It also highlighted microenvironment-centered
mechanisms dictating indolence or aggressiveness of early lesions and how spatial
geography impacts stromal attributes and function. The prognostic and therapeutic
implications as well as potential vulnerabilities within the heterogeneous tumor
microenvironment were also discussed. These broad topics were included in this
workshop as an effort to identify current challenges and knowledge gaps in the field.

INTRODUCTION

these approaches. Aggressive tumor phenotypes resulting
from targeted therapy, such as small cell lung cancers
and neuroendocrine prostate tumors following EGFRand AR-targeted inhibition [7, 8], respectively, prompted
the community to conclude that narrow tumor cell and
mutational status-centric approaches alone are unlikely
to succeed. The realization that successful combination
therapies in broad tumor types required an understanding
of the complexity of tumor-tumor microenvironment
(TME) dynamics and heterogeneity led to the development
of immune-oncology and checkpoint inhibitors. The
availability of research tools, experimental models, and
clinical reagents in the field of immunology has enabled
the rapid rise and validation of novel mechanism-based
approaches to modulate the immune microenvironment.
The delivery of durable remission induced by antiprogrammed cell death protein 1 (PD-1)/programmed
death-ligand 1 (PD-L1) and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) immune checkpoint
inhibitors in a subset of cancer types and patients has
motivated many basic and translational investigators to
focus their attention and resources towards studying the
role of the immune cell-tumor interplay in cancer growth,
progression, and recurrence [9–11]. However, only a
subset of patients benefit from immunotherapies and little
is known about the contribution of non-immune stromal
cell types and extracellular matrix components to these
processes, and even less is known about how these stromal
functions and interactions differ throughout each stage of
disease progression [11, 12]. Nevertheless, these successes
raise the possibility that further disease altering targets
reside in the TME, awaiting discovery.
Limited, yet pivotal studies demonstrating the
importance of non-immune stromal components in
shaping the fate of tumors exist, but remain poorly
understood and underpowered. Examples of work that
must be expanded include understanding the role of nonimmune stroma in regulating immune cell recruitment
to tumor sites, driving chronic inflammation-induced
DNA damage in preneoplasia, characterizing and
tracing different carcinoma-associated fibroblasts (CAF)
functional subtypes and their roles in different states as
both promoters and suppressors of tumor progression,

The last two decades have seen significant gains
in unveiling the crosstalk between cancer cells and the
stroma within which they reside. This complex mixture
of interacting cells can be considered as a dynamic
multidimensional ecosystem that regulates tumor growth,
inherent and acquired plasticity/heterogeneity, invasion,
and metastasis. The expansion of cancer research
beyond a cell autonomous-based model has enabled the
identification and characterization of a wide range of
cell types including fibroblasts, immune, endothelial,
neuronal, and specialized mesenchymal cells that regulate
the formation of a tumor-permissive and therapy-resistant
environment. In addition, a deeper appreciation for the
role that the extracellular matrix (ECM) plays in this
ecosystem has emerged. Despite these advances, much of
the scientific focus has remained primarily centered on the
tumor cells and on driver mutations that dictate stromal
reprogramming to support tumor growth. These include
oncogene-mediated tumor cell proliferation, reactive
oxygen species (ROS)/hypoxia-induced regulation of
the endothelium, inflammation-associated angiogenesis
and immune-suppression, and metabolic reprogramming
of stromal fibroblasts and adipocytes to offset tumor
cell nutrient deprivation [1–5]. Studies in these areas
have collectively uncovered numerous mechanisms by
which cancer cells manipulate the microenvironment to
support tumor growth. However, many aspects of the
biological alterations that arise in stromal cell types or in
the extracellular matrix components that may drive cancer
initiation or progression remain poorly understood.
The traditional view of driver mutations
within incipient tumor cells instructing each step of
tumorigenesis has influenced basic cancer researchers
and drug developers alike to focus on genetically and
molecularly profiling tumor cell autonomous mechanisms
for targetable vulnerabilities. The foundational principle
of “a tumor cell as an organizer” [6] also gave rise to
precision medicine as a promising blueprint and path
forward to more effective mutation- or target-specific
therapeutic strategies. Unfortunately, only modest
improvements in clinical outcomes have resulted from
www.oncotarget.com
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and the direct causal relationship between acellular
stroma, ECM remodeling and/or age-related senescenceassociated secretory phenotype (SASP) in inducing a
field-effect conducive to malignant conversion.
An ongoing challenge in studying these nonimmune stromal programs is that the models are still
limited. Appropriate and highly specific Cre-drivers that
allow for dynamic fate mapping of these cells are often
lacking. Limited studies have genetically manipulated
these stromal cell types in an unbiased manner using
shRNA and/or CRISPR approaches. This is essential
for discovering new functional aspects of stroma-tumor
crosstalk to move it from correlation to causality. Current
models that will enable these discoveries include more
rapid mouse transgenic models, complex organoid models,
as well as zebrafish and flies, the latter of which are
particularly amenable to screens of this sort.
Expanding the notion that stroma, along with the
tumor cells, co-organizes all stages of tumorigenesis
will lay the foundation for a broad spatial and temporal
understanding of the complete TME from initiation
through metastasis. In order to assess the challenges
associated with this goal, the NCI’s Division of Cancer
Biology sponsored a workshop that built upon the advances
in the immune-oncology realm and emphasized nonimmune stromal components. The workshop highlighted
the critical functions of the non-immune stromal cell types
and ECM in regulating heterogeneity and tumor cell fate
throughout initiation, progression, and therapy resistance.
The workshop not only explored the multifaceted role of
stroma in suppressing and/or supporting tumorigenesis
in early and advanced stage cancers, but also considered
emerging themes of stromal plasticity and positiondependent functions of stromal subtypes in driving
disease progression, resistance to therapy, and as possible
clinical targets of vulnerability. These workshop topics
were consolidated within five themes that addressed key
scientific and technical challenges related to 1) stromalcentric arbiters of tumor progression and suppression; 2)
the unique biology of early lesions in regulating indolence
versus aggressiveness; 3) stromal plasticity and its role in
regulating the fate of the tumor mass; 4) the significance of
stromal cell geography and architecture in cancer; and 5)
clinical implications of microenvironmental heterogeneity.

the microenvironment and important leads are beginning
to emerge that elucidate distinct functions of different
subtypes in these diametrically opposing functions. In
the first talk of the session, Raghu Kalluri highlighted the
functional diversity of tumor-restraining (αSMA+) and
tumor-promoting (FAP+) CAF subtypes in a mouse model
of pancreatic ductal adenocarcinoma (PDAC). αSMA+
CAFs predominantly modulate ECM production, facilitate
cell-ECM adhesion, and regulate adaptive immunity [13].
Simon Hayward shifted the focus to human prostate
cancer models and provided evidence of CAF subtypes
with distinct expression signatures revealed by single cell
RNA-seq analysis. CAF clusters differ in their chemokine/
cytokine profiles, leading to cluster-specific effects on
the microenvironment – such as macrophage recruitment
via high CCL2 expressing CAFs or modulation of
inflammatory cells by high CXCL12-expressing CAFs.
Specific populations of recruited populations (depending
on the CAF subtype) can produce distinct factors that
will shape the tumor and/or microenvironment in distinct
ways – e.g., macrophage-derived pro-tumorigenic factors,
recruitment of other immune cell types that promote the
M2-macrophage phenotype [14].
In her presentation, Ellen Puré focused on reactive
CAFs expressing fibroblast activation protein positive
(FAP+) in mouse PDAC. In contrast to normal stromal
cells that maintain epithelial integrity and confer tumor
resistance, FAP+ fibroblasts have immunosuppressive
and tumor promoting properties. Indeed, both the Puré
and Kalluri laboratories have provided evidence that
human PDAC patients with FAP+ fibroblasts have
decreased survival compared to αSMA+ fibroblasts [13,
15]. FAP+ fibroblasts display increased ECM alignment
[16] and synthesis, yet lower contractility and ECM
crosslinking, while displaying higher levels of paracrine
growth factors and inflammatory gene expression profiles
[17]. Mechanistically, Puré highlighted a novel ECMinformed stromagenic switch – regulated by multiple
factors including substratum stiffness, PDGF, TGFβ,
sonic hedgehog, and osteopontin – that contributes
to CAF heterogeneity and is a key component of the
transition from a tumor-resistant to a tumor-permissive
microenvironment [18].
David Tuveson discussed findings from his team
involving the identification of additional CAF subtypes
classified as either myogenic myCAFs, inflammatory
iCAFs, or the most recently isolated and characterized
antigen presenting apCAFs that express MHC class II
and CD74 and are capable of activating CD4+ T cells,
but lack other immune related genes including classical
co-stimulatory molecules [19, 20]. Studies by his group
using 3D organoid and mouse models suggest that CAF
heterogeneity is in part driven by IL-1β and TGFβ
antagonism, resulting in iCAFs and myCAFs that either
promote or inhibit tumor growth, respectively [21].
Single-cell mRNA-seq of human PDAC also putatively

Stromal-centric arbiters of tumor progression
and suppression
Stroma contributes to both suppressing and
promoting tumor progression, yet what cell subtypes,
ECM components, and underlying mechanisms regulate
tumor fate in varying contexts, including aging, genetic
background, and systemic comorbidities, remain illdefined. Studies conducted on fibroblasts and CAFs as
a major stromal element have contributed significantly
in the recent past to characterizing the heterogeneity of
www.oncotarget.com
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identified these two CAF subpopulations [19]. He further
highlighted the inherent, position-dependent plasticity
between CAF subtypes, suggesting these are functional
fibroblastic states, as opposed to static fibroblast types.
The topic of cellular plasticity was expanded further
by Ashani Weeraratna in her discussions of the aging
stroma in a mouse model of melanoma. She summarized
data that suggest age-associated events contribute to
altering the function of CAFs in a tissue-specific manner
and with important implications to not just tumorigenesis
and metastasis but also therapeutic outcomes. For instance,
aged lung fibroblasts (but not aged skin fibroblasts
from human donors) drive proliferation via induction
of canonical Wnt signaling [22]. In contrast, aged skin
fibroblasts exhibit enhanced sFRP2-driven non-canonical
Wnt signaling that triggers a phenotypic switch to a nonproliferative, yet highly invasive and BRAFi-resistant
mesenchymal state [22]. This BRAFi/MEKi resistance
is further propagated by the secretion of lipids by aged
fibroblasts, which drive metabolic changes in melanoma
cells in aged microenvironment (Alicea, Rebecca et al.
2020). Targeting these age-related changes overcame
therapy resistance in animal models, suggesting that the
TME may provide a rich source of targetable moieties.
Fibroblasts and other stromal cell types in the tumor
microenvironment acquire pro- and/or anti-tumorigenic
phenotypes that impact carcinoma growth. Research
in this area has identified heterogeneity in CAF marker
expression and function, altered functions of fibroblasts
based on tissue source, and plasticity of fibroblasts among
cell states. A greater understanding of this functional
heterogeneity and determining the degree of plasticity in
other stromal cell types will elucidate novel mechanisms
of tumor promotion and/or suppression, which may have
therapeutic potential.

revealed that notch signaling drives mitosis in these
polyploid cells [24]. These studies provide evidence
that signaling events within specific microenvironments
can enable tumor formation. Understanding the “tumor
hotspot” and “tumor coldspot” microenvironments and
what controls the definition of these regions may aid in
cancer prevention or have therapeutic potential.
Philip Beachy highlighted work from his group
demonstrating stromal suppression of growth in tumors of
endodermal origin. In bladder cancer, tumors are almost
completely clonal in origin, and using a mouse bladder
cancer model his group determined that sonic hedgehog
(Shh)-expressing cells act as long-term stem cells that
regenerate the bladder epithelium via Wnt signaling
[25, 26]. Precancerous bladder epithelium is still Shh+
but expression is lost in invasive carcinoma [26]. The
transition to invasive carcinoma may be linked to loss of
bone morphogenic proteins (BMP) in the adjacent stromal
tissue, since BMP treatment promotes differentiation and
blocks invasion in a mouse model of bladder cancer [26].
Another approach to investigating stromal
involvement in early cancer lesions was described by
Mara Sherman, who studies stromal evolution with
pancreatic stellate cells (PSCs). Work by her group is
focused on understanding the origins of fibroblasts within
the TME in mouse PDAC. PSCs give rise to the PDAC
CAF phenotype, but other non-PSC-derived CAFs exist as
well. Using known markers of fibroblasts, such as desmin
and podoplanin (PDPN), she indicated that some PDAC
CAFs were PSC-derived while other CAFs were PDPNpositive, non-PSC-derived CAFs [27]. She provided new
evidence that activated PSCs contain less lipid droplets
compared to pre-activated, and fatty acid binding protein 4
(FABP4) may be used as a marker for PSC-derived CAFs
in PDAC tissues [28]. However, more work is needed
to identify reliable markers for various CAF subsets to
further understand this heterogeneity.
The discussion of this session was expanded further
by Ken Lau, who uses computational modeling in colon
cancer to identify CAF-cancer cell interactions that
drive tumor progression [29]. His studies indicate that
CAFs dominate the signaling networks of cell surface
receptor-ligand interactions, specifically during epithelialmesenchymal transition (EMT) and in inflammatory
nodules (unpublished data). Noninvasive colon cancer cells
may also express EMT markers, so these are not unique to
metastatic cells. His laboratory identified that PDGFRα+
CAFs are adjacent to cancer cells in colon cancer tissue
specimens while αSMA+ myofibroblasts are more distant,
indicating potentially unique functions of these fibroblast
subsets as the disease progresses and underscoring the
importance of geographic location within a developing and
metastasizing tumor (unpublished data). Research by the
Lau group and others in this session highlighted the exciting
opportunities for discovery in the area of early-stage tumor
biology. Further investigation of stromal evolution is

Biology of early lesions: indolence versus
aggressiveness
It has become increasingly clear that the TME
changes throughout disease progression, but the
involvement of stromal cells is primarily studied with
regard to established and more advanced stages of cancer
(e.g., metastasis). The contribution of stromal cells and the
ECM to tumor initiation has not been widely studied, but
some research in this area using diverse approaches has
opened exciting avenues for further investigation.
Wu-Min Deng actively investigates tissue
environments which are susceptible or resistant to tumor
formation using a Drosophila model. He described that,
upon knockdown of a tumor suppressor gene scrib,
specific regions within developing fly tissues would
reject tumor growth while other regions would allow
tumor growth. This identified “tumor hotspots” in which
JAK/STAT signaling was determined to be elevated [23,
24]. Further analysis of transition cells of imaginal rings
www.oncotarget.com
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necessary to understand the biological importance to tumor
formation at different stages as well as to evaluate stagespecific therapeutic implications in these diseases.

are cytokeratin+CD45+ make up more than 90% of
circulating cancer cells [32]. This discovery suggests
that fusogenic events between CD45- epithelial cells and
CD45+ macrophages are at play in the TME in addition
to more widely appreciated cell-cell interactions and that
these events may impact tumor progression.
Significant efforts are currently in progress to target
immune cells, so discussions at this meeting put greater
emphasis on other cell types in the microenvironment
that have not been so widely studied. Adipose tissue, for
instance, is very dynamic and may serve as a nutrient source
for cancer cells. Ernst Lengyel works to understand the
microenvironmental contributions to human ovarian cancer
metastasis and the metabolic co-dependencies between
cancer and stromal cells. Metastasis to the omentum,
the common site in this disease, leads to the localized
disappearance of adipose tissue in the affected area. Dr.
Lengyel’s group has provided evidence that this loss is
likely due to the contributions of adipose tissue lipids and
FABP4 to the tumor cells [33]. Ovarian cancer cells become
loaded with lipid droplets after co-culture with adipocytes
[34]. Similarly, the Hayward lab shows that prostate CAFs
also maintain increased lipid droplet density compared to
normal prostate fibroblasts, which aid in prostate cancer cell
growth in vitro [35, 36]. Conversely, activation of primary
PSCs yielded significantly less lipid droplets compared to
pre-activated PSCs, but nevertheless suggest a link between
stroma-derived lipids and tumor metabolism and growth
[28]. However, the source of these lipids, the role they play
in individual stromal cell types, and whether these differ in
unique cancer types remain to be seen.
To further elucidate the role of lipids and adipose
tissue in the TME, James Granneman’s laboratory
investigates adipogenic niches and the stromal/immune
cells that are key to adipose tissue maintenance,
remodeling, and may play a role in tumor progression.
scRNA-seq of mouse adipose tissue by his group identified
two major adipocyte stem cell (ASC) subpopulations,
ASC1 and ASC2, in epididymal and inguinal white
adipose tissue that express different collagens and trophic
factors, such as neurotrophin 3 and bone morphogen 7
[37]. The ASC1 subpopulation expresses higher levels of
PPARγ, a master regulator of adipogenesis, as well as the
adipogenesis markers caveolin-1 and G0/G1 switch 2 –
and appear to be primed for adipogenesis compared with
ASC2 cells. The Granneman lab has begun to map the
trajectory of adipose tissue in mouse cancer models. In
these studies, tumor-bearing mammary fat pads underwent
ASC population shifts from ASC2 to ASC1 in tumorbearing mice as well as changes in macrophage expression
patterns linked to inflammatory responses, such as
increased Trem2 and Irf8 [37]. This work aims to discover
how adipose tissue changes in cancer and mechanisms by
which this evolution contributes to malignant progression.
Richard White further expanded the discussion of
stromal-cancer cell interactions by discussing his work

Stromal plasticity and communication
Complete knowledge of the TME requires an
understanding of the many cell types and interactions
within it. Unfortunately, the complexity of these
interactions makes this work technically and conceptually
difficult. Some of these interactions cannot be adequately
studied because appropriate tools have not yet been
developed. Thus, one of the objectives of this meeting
was to discuss interactions between all cell types within
the TME, including fibroblasts, adipocytes, immune
cells, endothelial cells, nerves, normal epithelial cells,
and cancer cells, as well as to discuss current limitations
associated with researching intercellular communication.
Throughout the last decade, our understanding of
cancer-immune cell interactions has been significantly
advanced and has even led to successful new therapeutic
strategies. PD-L1 targeting is one example of recently
discovered therapeutic options, but clinical applications
of PD-1/PD-L1 therapies have identified limitations,
specifically by driving resistance mechanisms in tumors
[11]. Current work by Jorge Moscat’s research group
has shown that PD-L1 treatment works by revitalizing
CD8+ T cell infiltration in a mouse model of serrated
colorectal cancer, but only in young mice in which tumors
have not yet developed a reactive stroma [30]. In older
mice with highly desmoplastic tumors, PD-L1 treatment
does not restore CD8+ T cells and consequently has no
curative activity. This finding suggests that dual stromal
activation impairs immune checkpoint blockade therapy,
which was demonstrated to be the case by Moscat’s lab
by targeting of TGFβ, which enhanced PD-L1 targeting
efficiency [30]. Furthermore, analysis of how stromal cells
may impair PD-L1 therapy suggests that CAF can block
antigen presentation. Consideration of additional stromal
contributors in this context as well as systemic factors,
such as age, will elucidate superior therapeutic options.
While the role of some immune cell populations,
notably T cells and tumor-associated macrophages, have
been widely studied in the context of the TME, this is an
active area of research in which novel findings continue
to evolve our understanding of immune cell-tumor cell
dynamics and their potential implications in shaping tumor
evolution. Melissa Wong and her group have recently
characterized a cell fusion of macrophages with cancer
cells [31]. These cancer hybrid cells acquire macrophage
gene expression profiles and retain macrophage behavior,
but are also capable of initiating tumors and can be
detected in peripheral blood of patients [31, 32]. While
most studies involving circulating tumor cells (CTCs)
use cytokeratin+CD45- as the schema for detecting
CTCs, Wong’s group discovered that hybrid cells that
www.oncotarget.com
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using zebrafish melanoma models. The zebrafish is ideal
for this given the optical transparency of the casper
strain, which allows for powerful in vivo imaging [38].
Melanomas are surrounded by two cell types organized
into a distinct geography, with keratinocytes above the
lesion and adipocytes below the lesion. Prior work from
the White lab showed that adipocytes are major drivers
of melanoma progression by donating fatty acids to the
tumor cell [39], which is consistent with other work in
ovarian cancer [40]. What is less understood is how the
keratinocytes, which are normal epithelial components
of skin, drive progression. Using a BRAFV600E induced
transgenic melanoma model [41] and real-time in vivo
imaging, the White lab found that tumor cells export a
variety of extracellular vesicles such as melanosomes
and exosomes into the seemingly normal keratinocytes.
The recipient keratinocytes then undergo reprogramming
and switch from a tumor suppressive to tumor promoting
role. These reprogrammed keratinocytes exhibit an
N-myc pluripotency signature and dramatic alterations
in chromatin structure. Although the absolute number of
keratinocytes that undergo such reprogramming is small,
their importance in promoting melanoma progression
highlights the need for a detailed understanding of the
“geography” of tumor-stroma interactions [42].
In other cancer models, such as renal cell carcinoma,
the environmental context of cancer epithelial cells
drastically influences the invasion potential of epithelial
tumor cells. David Beebe’s models that incorporate
compartmentalized epithelial and endothelial duct-based
organotypic platforms, indicate that incubation of tumor
epithelium with normal endothelium promotes invasion
of the endothelial cells. However, incubation of tumor
epithelium with cancer associated endothelium only
yields cancer cell invasion without endothelial invasion.
The Beebe lab continues to lead the development of cellcell interaction and microfluidic models for the study of
unanswered biological questions [43, 44]. Use of these
models and others will be essential to understanding
the role of specific stromal cell types, intercellular
communication, and the role of ECM components in the
TME.

destruction. Stromal stiffness, for instance, can signal
normal epithelial cells to adopt malignant phenotypes [49,
50], while dormant tumor cells have been suggested to
resist chemotherapy by residing within the perivascular
niche [51]. Therefore, a better understanding of tumor
architecture and histology can provide important
knowledge about how stromal cells organize themselves
around the tumor cells and dictate their function/
phenotype.
Despite recent technological advances, such as
imaging mass cytometry and co-detection by indexing
(CODEX) [52], histological analyses remain limited due
to reliance on pre-existing antibodies. To overcome this
limitation, Joakim Lundeberg has recently developed
Spatial Transcriptomics (Visium from 10X Genomics,
Inc.), a tool that combines tissue imaging with barcode
array-based sequence transcriptomics. This tool allows for
standard microscopy of fresh frozen sections to be coupled
with spatial mRNA-seq, and ultimately visualization of
imaging patterns, clonal tumor populations and stromal
areas within intact tissues. Key findings include the
identification of discrete stromal regions around prostate
tumors that were nonresponsive to treatment [53]. As
they expand the analysis, new fibroblast expression
datasets under development will help identify CAFs
of different origins and functions within the TME. The
spatial interaction between stroma and various tumor
subpopulations at the leading edge has recently been
investigated in squamous cell carcinoma [54].
Next, Kristian Pietras showed that breast cancer
CAFs from a mouse model are characterized by three
distinct transcriptional programs, potentially reflecting
unique spatial origins within the TME [55]. The largest
CAF populations were enriched for angiogenic genes
(vCAF) reflecting a perivascular origin. The second
most abundant CAF population showed a significant
increase in the expression of ECM-associated genes,
suggesting tissue-resident fibroblasts as the source for this
specific CAF subtype. The third, scarce CAF cluster was
characterized by the expression of development-associated
genes and were provisionally named developmental
CAFs (dCAF). dCAFs show some overlapping gene
expression with tumor epithelium, suggesting that dCAFs
may originate from cancer cells that underwent EMT.
The combination of Pietras’s CAF dataset with spatial
transcriptomics may provide interesting data regarding
the real spatial localization of these CAF subtypes within
the TME.
Ruth Scherz-Shouval discussed transcriptomic
data from a murine breast cancer model obtained using
single-cell RNA-seq at different time points along
tumor progression and metastasis. Her group identified
two distinct CAF populations, each of which could be
further dissected into subsets that change as tumors
progress. These CAF subtypes, sCAF and pCAF, were
characterized by high expression of S100A4 and PDPN,

The significance of stromal cell geography and
architecture
The late Dr. Patricia Keely revolutionized the TME
field by demonstrating that architectural organization of
the ECM (including tumor cell distribution/localization)
is fundamental to tumor cell-stromal cell interactions,
metastasis, and response to therapy [45–48]. A stromal/
ECM barrier or tumor cell location within the TME may
not only create nutrient/growth factor gradients, but
also serve as a source of exogenous physical forces that
may reprogram tumor cells and potentially function as a
barrier against cancer therapy and adaptive immune cell
www.oncotarget.com
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respectively, and found in both mouse and human breast
tumors. Interestingly, a higher sCAF/pCAF ratio was
indicative of better overall survival in human patients,
suggesting that the sCAF population may play a protective
role against tumor progression [56]. Identifying specific
subsets of CAFs that are associated with better therapeutic
response and survival will allow researchers to leverage
the function of these CAFs and bring precision treatment
to patients with tumor-permissive CAF subtypes within
their TME. However, as the characterization of CAF
subtypes advances, the field will need to put further effort
into standardizing the nomenclature and markers of these
unique CAF populations (i.e., lineages and functions).
Doing so will help integrate the findings from different/
independent research groups.
Katerina Politi shifted the focus to discuss how
tumor intrinsic-targeted therapies are impacted by the
organs affected by metastases. As mentioned above, these
approaches have limited benefits, since tumors may,
in part, undergo clonal selection upon targeted-therapy
eventually culminating in a more aggressive tumor. For
example, in EGFR-mutant lung tumors, resistance to first
and second generation tyrosine kinase inhibitors (TKIs)
is mostly driven by the emergence of a secondary T790M
mutation in EGFR. To overcome this resistance, a third
generation TKI, osimertinib, is currently used clinically,
but patients can still develop resistance and many of the
resistance mechanisms are poorly understood. To unravel
the underlying mechanism, Politi and colleagues are
investigating therapeutic responses in different metastatic
sites. Early data support the idea that the TME location
can impact sensitivity to TKIs. It is well known that
different tumor sites can differentially impact tumor
progression. Hence, the field needs to advance towards
a better characterization of the molecular and cellular
mechanisms that drive increased tumor progression in
an organ and location-specific manner. Concomitantly,
improved comprehension of the specific sites in the body
that more potently restrict tumor cell proliferation could
also provide valuable knowledge about stromal/tumor
interactions that drive tumor progression.
The meeting also tackled the question of endothelial
heterogeneity. Ying Zheng discussed the dynamic nature
of the tumor microvasculature and how it changes during
tumor progression. Zheng noted that many ongoing studies
still work with specific cell lines that do not recapitulate
the heterogeneity found in endothelial cells of different
tissues. It is also important to consider the interactions of
endothelial cells with their surroundings, which contain
diverse cell types, ECM, and geometric complexities.
Taking this into consideration, Zheng engineered a device
that allows endothelial cells to reconstruct 3D vessel
structures using fetal endothelial cells from different
tissues. This technology aided in determining that
endothelial cells with distinct tissue origins do indeed form
vessels with diverse architecture and unique transcription
www.oncotarget.com

profiles [57]. Studies regarding ECM influence on
microvasculature architecture and gene expression are
ongoing and will help elucidate the crosstalk between
endothelial cells originating in different organs and their
surroundings. Many questions still need to be addressed
in order to completely understand microvasculature
formation and function in tumors, including endothelial
cell plasticity and how tumor cell or tissue location
impacts endothelial cell behavior and microvasculature
structure and function.
The present level of characterization of CAFs,
adipocytes and endothelial cells has brought valuable,
but less than comprehensive information about their
function within the TME. Nevertheless, it will help
develop a necessary expansion in the field to identify new
opportunities for targeted therapies. Better understanding
the role of the non-immune stroma in shaping the
microenvironment prior to the appearance of a tumor
is also pivotal to unravelling the mechanisms driving
tumorigenesis. A key issue is the high degree of stromal
cell plasticity driven by multiple environmental vectors,
creating a challenge to working with them in an ex vivo
setting. Another looming challenge is to define cell states
versus subtypes, particularly in CAFs. Also, work toward
identifying triggers of cellular plasticity versus a more
permanent epigenetic state is needed. This work will lay
the groundwork for the field to move more deeply into the
mechanisms that drive changes in the TME and impact
tumorigenesis.

Prognostic and therapeutic implications of
microenvironmental heterogeneity
During the final session, discussions were focused
on the implications of current cancer therapy in the TME.
Despite recent advances in targeted and immunotherapies,
the core of cancer treatment is based on genotoxic agents,
such as ionizing radiation and chemotherapy. Those agents
exert systemic and local damage in non-tumor cells that
consequently impact therapy-associated comorbidities
and cancer recurrence. In this context, Sheila Stewart
discussed her findings related to the impact of senescence
in chemotherapy-induced bone loss, a common
comorbidity in cancer patients. Using a genetic mouse
model, her team found that elimination of senescent cells
that arise after chemotherapy prevented bone loss [58]. In
addition, targeting SASP pathways using pharmacological
inhibition of p38MAPK/MK2 signaling also limited
chemotherapy-induced side effects [58]. Senescence is
not only triggered by chemotherapy but occurs normally
in healthy individuals, as part of the aging process, and
may directly impact tumorigenesis. Senescent fibroblasts
upon SASP expression behave similarly to CAF regarding
their ability to directly support tumor growth [59]. Stewart
highlighted that limiting SASP signaling pathways reduces
metastatic growth in a breast cancer setting. Her group
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found that inhibition of p38MAPK/MK2 signaling
restrained metastatic growth in the bone and visceral
organs, through tumor cell-independent mechanisms
[60]. However, the stromal cells where p38MAPK/MK2
signaling exerts a deleterious role in metastatic growth
remain to be elucidated.
Besides SASP, chemotherapy-induced genotoxic
stress can trigger a DNA damage secretory program
(DDSP) – very similar to SASP but not associated with
cell cycle arrest and/or p16 signaling– releasing numerous
inflammatory (IL-6/8), angiogenic (VEGF, CXCL1),
mitogenic (amphiregulin), pro-EMT (HGF) and chemopreventative factors. Focusing on the potential effects of
genotoxic stress in the TME, Peter Nelson showed that
human prostate fibroblasts upregulate numerous protumorigenic factors upon a variety of genotoxic stimuli.
Among the released factors, WNT ligands attenuate a
cytotoxic chemotherapy effect in vivo when expressed
in the prostate TME [61]. He highlighted the therapeutic
potential of targeting these chemotherapy-induced
factors, many of which are downstream of NF-κB and
mTOR pathways. Despite the fact that NF-κB does not
currently constitute a viable target, mTOR signaling can
be targeted by many available drugs (e.g., rapamycin).
Interestingly, fibroblasts that have been previously treated
with rapamycin do not confer chemotherapy resistance
to prostate cancer cells in vitro and in vivo. These
data support ongoing clinical trials to assess whether
rapamycin-induced inhibition of DDSP in prostate cancer
patients under chemotherapy treatment can improve
response. Other druggable DDSP pathways, including
PARP inhibition to attenuate the DDSP and the NKG2DMIC-MMP axis to eliminate damaged cells with immunesuppressive phenotypes, are also under consideration for
future studies to identify new opportunities for stromatargeted therapies [62].
Neil Bhowmick expanded on the stromal
considerations for prostate cancer therapy by presenting
findings that demonstrated chemotherapy-triggered
crosstalk between CAFs and tumor cells. His team found
that docetaxel induces mitophagy and ER stress in prostate
tumor cells, leading to secretion of mitochondrial DNA
(mtDNA) [63]. This results in TLR9 activation in CAFs
and release of C3a, a complement protein. Interestingly,
C3a-induced activation of the C3a receptor in prostate
cancer cells drives docetaxel resistance in mouse models.
mtDNA was also found in the plasma of docetaxel-treated
patients supporting the hypothesis that therapy resistance
in prostate cancer patients may occur by this crosstalk
[63]. In mouse models, combination therapy of docetaxel
with a C3aR inhibitor showed increased efficacy in
limiting tumor growth when compared to docetaxel alone.
Future studies to unravel stromal-mediated chemotherapy
resistance mechanisms may support the development
of stroma-targeted therapies that improve current
chemotherapy response in different types of cancer.
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Finally, Edna Cukierman discussed the stromal
heterogeneity found in the desmoplastic environment of
pancreatic tumors. Her group found that fibroblastic cell
function depends on the fibroblastic ECM. She showed
that the desmoplastic ECM sustains the expression
of Netrin G1 in PDAC CAFs while tumor adjacent
fibroblasts cultured in “normal” ECM do not express
this protein. Netrin G1 is a glycosylphosphatidylinositolanchored protein known for its glutamatergic presynaptic function. Interestingly, the Netrin G1 binding
partner, NGL1, is overexpressed in pancreatic cancer
cells, suggesting a possible crosstalk between CAFs and
tumor cells through Netrin G1/NGL1 signaling axis [64].
Further investigation revealed that a lack of Netrin G1
in fibroblasts or lack of NGL1 in pancreatic cancer cells
severely affected the ability of the latter to survive upon
nutrient starvation. In addition, Netrin G1 expression
in CAFs, through downstream p38MAPK activation,
was found to be required to suppress NK cell-mediated
cytotoxicity in the same model. Further, her team revealed
that high expression levels of stromal Netrin G1 inversely
correlate with PDAC patient overall survival. Taken
together, the presented data indicate that Netrin G1+ CAFs
provide better PDAC cell survival in nutrient-deprived
environments, and means to escape from the immune
system. Notably, it highlights the multiple roles CAFs play
during tumor progression. As the field moves forward,
TME researchers can build upon these studies that show
stroma support tumor growth and resistance to treatment
and/or stress in multiple environments.

Outstanding questions
This meeting fostered discussions of the needs
and limitations of research currently focused on the
components of the TME. Participating individuals are
leading research programs to identify novel cell types,
pathways of cellular interactions, model systems suitable
for TME research questions, and to unravel heterogeneous
cell populations. However, investigation of the TME
components – and how they evolve throughout tumor
progression, their role as drivers or suppressors of
tumorigenesis, malignancy and/or partner with the tumor
mass as co-organizers in tumor growth and respond to
current therapeutics – remains limited. While progress has
been made by several research programs in identifying
novel CAF subpopulations, and initial traction is
beginning to emerge with endothelial cells and adipocytes,
standardized functional and molecular definitions for
fibroblast subtypes (and other non-immune cells) do
not yet exist. Tools to capture stromal heterogeneity
are limited due to variable isolation techniques and the
loss of cellular and microenvironmental context. Even
with scRNA-seq data acquired to-date, lack of uniform
analysis pipelines makes full utilization of the biological
implications of this data difficult.
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It would also be beneficial to create an accessible
catalog of all cell types, spatial context, mechanical
properties, and events that regulate them such that the field
may begin to interpret what constitutes a supportive or
resistant tumor stroma – or even sub-stromal compartments
such as the perivascular niche that may uniquely protect
tumor cells relative to other stromal regions. Similarly, it
is not yet understood when a stroma becomes supportive
of the tumorigenic process, when a suppressive stroma
is lost or reprogrammed, and what determines this
“stromagenic switch.” This includes the contribution of
lifestyle factors, aging, and drug treatments that are likely
to not only impact traditionally (and narrowly) defined
tissue-specific microenvironments but also more broadly
if the microenvironment is expanded to systemic effects as
well. Another consideration is the changes in stroma from
early (pre-neoplastic) disease through metastatic disease,
which likely abide by stage-specific regulatory networks
and yield unique changes for each cancer type. While many
microfluidic or other engineered model systems are being
developed to address the interactions of multiple cell types,
development of new models may be necessary to address
these fundamental questions.
Cells from multiple origins may perform similar
functions. We have discussed CAF heterogeneity broadly
in terms of function and marker expression, but these cells
may be derived from a variety of sources, including bone
marrow-derived mesenchymal stem cells, adipocytes, or
even cancer cells which have undergone EMT [5]. Despite
distinct origins, these precursors may converge into similar
CAF functions, reinforcing the importance of key stromal
cell functions in the TME.
Finally, we need to determine what therapeutic
opportunities exist within the TME that may improve the
current standard-of-care for each cancer type and disease stage.
Understanding some of the questions outlined above may
unveil new therapeutic strategies, but widely useful platforms
to test novel strategies both in primary and metastatic disease
settings are also necessary, particularly because a response
in the primary setting does not dictate a response in the
metastatic setting. Likewise, established tumors are not one
and the same as an early lesion, and are therefore unlikely to
follow the same set of “biological rules.” Since the TME is
complex and evolves with disease progression, there are many
opportunities for discovery. Ultimately, a greater research
effort in tumor stroma will lead to precision medicine with
optimal therapeutic intervention and better patient outcomes.
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